Loading patent…
AssigneeNovartis AG
InventorsBrian Granda, Amy Rayo, Connie Hong, Dattananda Chelur, Haihui Lu, Regis Cebe, Sunyoung Jang
Estimating the term…
The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.
A CD19 binding molecule that specifically binds to human CD19 and comprises an antibody or antigen-binding fragment thereof comprising CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, respectively, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19, respectively.
A CD19 binding molecule which is a trispecific binding molecule (TBM) comprising:
A CD19 binding molecule comprising:
A CD19 binding molecule comprising:
A CD19 binding molecule which is a trispecific binding molecule (TBM) comprising:
Dependencies are inferred from the claim text.